ASCO24 Updates: The Role of Neoadjuvant Treatment for MMR-Proficient/Deficient Colorectal Cancer

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Richard Kim, Professor at Moffitt Cancer Center, shares insights about their educational session on “Neoadjuvant Approach to Localized Colon Cancer: Ready for Prime Time?.”

Dr. Kim also presented a poster at this year’s meeting on “A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.” 

More videos and content from ASCO 2024 on OncoDaily.